English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Neuroendocrine tumors (NETs) are rare neoplasms that emerge mainly from the GI tract, pancreas and respiratory tract. The incidence of NETs has increased more than sixfold in the last decades. NETs typically express somatostatin receptors on their cell surface, which can be targeted by 'cold' somatostatin analogs for therapy or by 'hot' radiolabeled somatostatin analogs for tumor localization and treatment. 68-Gallium-DOTA peptides (DOTATATE, DOTATOC, DOTANOC) positron emission tomography/computed tomography is a highly accurate imaging modality for NETs that has been found to be more sensitive for NET detection than other imaging modalities. In the current review, we will discuss the clinical utility of 68-Gallium-DOTATATE positron emission tomography/computed tomography for the diagnosis and management of patients with NETs.

future oncology

The Utility of <sup>68</sup> Ga-DOTATATE Positron-Emission Tomography/Computed Tomography in the Diagnosis, Management, Follow-Up and Prognosis of Neuroendocrine Tumors

The Utility of 68 Ga-DOTATATE Positron-Emission Tomography/Computed Tomography in the Diagnosis, Management, Follow-Up and Prognosis of Neuroendocrine Tumors

The Utility of ⁶⁸ Ga-DOTATATE Positron-Emission Tomography/Computed Tomography in the Diagnosis, Management, Follow-Up and Prognosis of Neuroendocrine Tumors